New York, United States, July 21, 2022 (GLOBE NEWSWIRE) — Vascular endothelial Growth factor, also known as VEGF, is a naturally occurring protein in the human body responsible for forming and maintaining new blood vessels. Under abnormal conditions, such as diabetic retinopathy, blood vessel obstruction, or age-related macular degeneration, it causes the formation of abnormal blood vessels, which can bleed, leak, and eventually lead to scar formation and vision loss.
Therapeutics that inhibit the activity of vascular endothelial growth factors are known as anti-vascular endothelial growth factor therapeutics or anti-VEGF therapeutics. This class of drugs is used to treat numerous diseases, including cancer and ophthalmic conditions such as diabetic retinopathies, age-related macular edema, and retinal vein occlusion. When anti-VEGF agents are administered under the appropriate conditions, they counteract the action of VEGF at the molecular level, resulting in a reduction in morbidity.
During growth and development and in diseases such as cancer, diabetes, and macular degeneration, the vascular endothelial growth factor (VEGF) is regarded as the master regulator of angiogenesis. Anti-VEGF is anticipated to be driven by technological advances in the treatment of ophthalmic diseases, an increase in the prevalence of ophthalmic and chronic diseases associated with indications such as age-related macular degeneration, retinal vein occlusion, and diabetic retinopathies, and…
